Sandhya Krishnan

Sandhya Krishnan

Auto-generated profile, based on publicly available information

Sandhya Krishnan

Sarcoma Medical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLSalah-Eddine LAMHAMEDI-CHERRADI
Salah-Eddine LAMHAMEDI-CHERRADI
MMMayinuer Maitituoheti
Mayinuer Maitituoheti
BMBrian A. Menegaz
Brian A. Menegaz
SKSandhya Krishnan
Sandhya Krishnan
AVAmelia M. Vetter
Amelia M. Vetter
JLJoseph Ludwig
Joseph Ludwig
Desmoplastic small round cell tumor (DSRCT) is an aggressive, usually incurable sarcoma subtype that predominantly occurs in post-pubertal young males. Recent evidence suggests that the androgen receptor (AR) can promote tumor progression in DSRCTs. However, the mechanism of AR-induced oncogenic stimulation remains undetermined. Herein, we demonstrate that enzalutamide and AR-directed antisense oligonucleotides (AR-ASO) block 5α-dihydrotestosterone (DHT)-induced DSRCT cell proliferation and reduce xenograft tumor burden. Gene expression analysis and chromatin immunoprecipitation sequencing (ChIP-seq) were performed to elucidate how AR signaling regulates cellular epigenetic programs. Remarkably, ChIP-seq revealed novel DSRCT-specific AR DNA binding sites adjacent to key oncogenic regulators, including WT1 (the C-terminal partner of the pathognomonic fusion protein) and FOXF1. Additionally, AR occupied enhancer sites that regulate the Wnt pathway, neural differentiation, and embryonic organ development, implicating AR in dysfunctional cell lineage commitment. Our findings have direct clinical implications given the widespread availability of FDA-approved androgen-targeted agents used for prostate cancer.

6 January 2021 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
SLSalah-Eddine LAMHAMEDI-CHERRADI
Salah-Eddine LAMHAMEDI-CHERRADI
SMSana Mohiuddin
Sana Mohiuddin
DMDhruva K. Mishra
Dhruva K. Mishra
SKSandhya Krishnan
Sandhya Krishnan
AVAlejandra Ruiz Velasco
Alejandra Ruiz Velasco
JLJoseph Ludwig
Joseph Ludwig
Osteosarcoma (OS) is a molecularly heterogeneous, aggressive, poorly differentiated pediatric bone cancer that frequently spreads to the lung. Relatively little is known about phenotypic and epigenetic changes that promote lung metastases. To identify key drivers of metastasis, we studied human CCH-OS-D OS cells within a previously described rat acellular lung (ACL) model that preserves the native lung architecture, extracellular matrix, and capillary network. This system identified a subset of cells—termed derived circulating tumor cells (dCTCs)—that can migrate, intravasate, and spread within a bioreactor-perfused capillary network. Remarkably, dCTCs highly expressed epithelial-to-mesenchymal transition (EMT)-associated transcription factors (EMT-TFs), such as ZEB1, TWIST, and SOX9, which suggests that they undergo cellular reprogramming toward a less differentiated state by coopting the same epigenetic machinery used by carcinomas. Since YAP/TAZ and AXL tightly regulate the fate and plasticity of normal mesenchymal cells in response to microenvironmental cues, we explored whether these proteins contributed to OS metastatic potential using an isogenic pair of human OS cell lines that differ in AXL expression. We show that AXL inhibition significantly reduced the number of MG63.2 pulmonary metastases in murine models. Collectively, we present a laboratory-based method to detect and characterize a pure population of dCTCs, which provides a unique opportunity to study how OS cell fate and differentiation contributes to metastatic potential. Though the important step of clinical validation remains, our identification of AXL, ZEB1, and TWIST upregulation raises the tantalizing prospect that EMT-TF-directed therapies might expand the arsenal of therapies used to combat advanced-stage OS.

22 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
DTDanh Truong
Danh Truong
SLSalah-Eddine Lamhamedi-Cherradi
Salah-Eddine Lamhamedi-Cherradi
RPRobert W. Porter
Robert W. Porter
SKSandhya Krishnan
Sandhya Krishnan
JSJyothishmathi Swaminathan
Jyothishmathi Swaminathan
JLJoseph Ludwig
Joseph Ludwig
Background Single-cell RNA-seq has emerged as an innovative technology used to study complex tissues and characterize cell types, states, and lineages at a single-cell level. Rapid adoption of this technology has led to a flurry of research creating single-cell atlases for many organs, cancers, and developmental models. Despite the tremendous success of this technology, sarcomas, rare cancers of mesenchymal origin, have not yet widely benefited from the adoption of single-cell RNA-seq. Due to their rarity, obtaining fresh clinical specimens is challenging. Single-nucleus RNA-seq could remove limitations from obtaining fresh tissue and enable immediate processing of archival tissue. However, biases may exist during dissociation of either fresh or frozen specimens that can hinder reproducible results and introduce technical or biological artifacts. Results To address these questions, we systematically assessed dissociation methods across different sarcoma subtypes. Here, we compare gene expression from single-cell and single-nucleus RNA-sequencing of 125,831 whole-cells and nuclei from Ewing’s sarcoma, desmoplastic small round cell tumor, and osteosarcoma patient-derived xenografts. We detected warm dissociation artifacts from single-cell samples and gene length bias in single-nucleus samples. Classic sarcoma gene signatures were observed regardless of dissociation method. Finally, we show that dissociation method biases can be computationally corrected. Conclusions We highlighted transcriptional biases, including warm dissociation and gene-length biases, introduced by any dissociation method for various sarcoma subtypes. This work will inform researchers on choice of dissociation method and careful interpretation of data due to dissociation biases.

1 October 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Open access
PDF file
LML.S.K. Mahadevan
L.S.K. Mahadevan
NSN. Sahoo
N. Sahoo
MAM.L. Aliru
M.L. Aliru
SKS. Krishnan
S. Krishnan
Radiation therapy has been shown to induce immune-mediated tumor regression by multiple mechanisms. One of the mechanisms is to trigger an immunogenic phenotype characterized by upregulation of cell surface immune co-stimulators, antigen presenting machinery and checkpoint molecules that primes cells for subsequent elimination by cytotoxic T cells. The LET of the proton beam varies with the depth of dose deposition. Prior studies comparing proton radiation to photon radiation have failed to identify a stronger immunogenic phenotype with protons. However, the linear energy transfer (LET) was comparable for both modalities. We asked whether immunogenic phenotype induction would be different with higher LET, one that is typically noted towards the end of the Bragg peak of protons.